REC604a-Novel Adjuvanted Recombinant HPV 4-valent vaccine

The REC604a is equipped with the novel adjuvanted BFA04 independently developed by the Company, which aims to reduce the dose of vaccination by enhancing the immunogenicity and cross-protection effects. Reducing dose number helps save costs and increase vaccination rates, which is recommended by regulatory agencies such as the WHO. We have obtained the implied license for conducting clinical trials for REC604a in China, and will adopt a more reasonable follow-up development strategy by taking into account market demand and relevant regulatory guidance.